Express Pharma

Optimus Pharma gets DCGI nod for Phase III trials of Molnupiravir for COVID-19 treatment

As per the clinical trial protocol approved, 2500 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care

0 463